Management ChangeMay 19, 2026, 04:32 PM
Vistagen Appoints Angel S. Angelov as Chief Medical Officer
AI Summary
Vistagen Therapeutics, Inc. announced the appointment of Angel S. Angelov, M.D., MBA, as its new Chief Medical Officer, effective May 18, 2026. Dr. Angelov brings over two decades of leadership experience in clinical development and medical affairs from companies like Theranica, Karuna Therapeutics, and Neurocrine Biosciences. His compensation package includes an annual base salary of $425,000, a $50,000 signing bonus, eligibility for an annual cash bonus, and an inducement grant of stock options to purchase 150,000 shares.
Key Highlights
- Vistagen appointed Angel S. Angelov, M.D., MBA as Chief Medical Officer, effective May 18, 2026.
- Dr. Angelov previously served as CMO at Theranica and held leadership roles at Karuna Therapeutics and Neurocrine Biosciences.
- His starting annual base salary is $425,000.
- He will receive a $50,000 signing bonus, paid in two tranches.
- He is eligible for an annual discretionary cash bonus with an initial target of 45% of his base salary.
- Dr. Angelov was granted stock options to purchase 150,000 shares of common stock.
- The stock options have an exercise price of $0.5955 per share and vest over four years.
- Vistagen and Dr. Angelov entered into an Indemnification Agreement.
Price Impact
More from VTGN